May 15 |
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
|
May 10 |
Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
|
May 9 |
Monte Rosa Therapeutics GAAP EPS of -$0.53 beats by $0.04
|
May 9 |
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
|
May 2 |
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
|
Apr 10 |
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
|
Apr 4 |
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
|
Mar 22 |
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
|
Mar 19 |
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
|
Mar 16 |
Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results
|